SCHEMBL29907269

SCHEMBL29907269

COc1cc(C)c(Br)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NNMT P40261 1/20 0.50
CYP2A6 P11509 2/20 0.40
PIK3CA P42336 1/20 0.36
GABRP O00591 1/20 0.36
GABRD O14764 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRB1 P18505 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA5 P31644 1/20 0.36
GABRA3 P34903 1/20 0.36
GABRA2 P47869 1/20 0.36
GABRB2 P47870 1/20 0.36
GABRA4 P48169 1/20 0.36
GABRE P78334 1/20 0.36
GABRA6 Q16445 1/20 0.36
GABRG1 Q8N1C3 1/20 0.36
GABRG3 Q99928 1/20 0.36
GABRQ Q9UN88 1/20 0.36
MEN1 O00255 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL364584 1.00 NNMT (0.50) NNMTCYP2A6PIK3CAGABRPGABRD
SCHEMBL957634 0.92 NNMT (0.49) NNMTCYP2A6PIK3CAGABRPGABRD
SCHEMBL29911687 0.83 NNMT (0.46) NNMTCYP2A6GABRPGABRDGABRA1
SCHEMBL14276053 0.83 NNMT (0.46) NNMTCYP2A6GABRPGABRDGABRA1
SCHEMBL2614474 0.79 NNMT (0.55) NNMTCYP2A6PIK3CAGABRPGABRD
SCHEMBL2837318 0.79 GABRA1 (0.41) NNMTPIK3CAGABRPGABRDGABRA1
SCHEMBL1459785 0.79 GABRA1 (0.39) NNMTPIK3CAGABRPGABRDGABRA1
SCHEMBL1458970 0.79 PIK3CA (0.38) NNMTPIK3CAMEN1KMT2AHAO1
SCHEMBL3668216 0.78 UHRF1 (0.56) NNMTCYP2A6PIK3CAGABRPGABRD
SCHEMBL29492737 0.78 UHRF1 (0.56) NNMTCYP2A6PIK3CAGABRPGABRD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4719597-A1 SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED CALCIUM ION CHANNEL CAV2.3 ANTAGONISTS Lario Therapeutics Limited (GB) 2026-04-08 EP disclosed
WO-2025043191-A1 PRC2 INHIBITORS FOR USE IN TREATING SICKLE CELL DISEASE ORIC PHARMACEUTICALS, INC. (US) 2025-02-27 WO disclosed
WO-2024246523-A1 SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED CALCIUM ION CHANNEL CAV2.3 ANTAGONISTS LARIO THERAPEUTICS LIMITED (GB) 2024-12-05 WO disclosed
EP-4463459-A1 STAT MODULATORS AND USES THEREOF Recludix Pharma, Inc. (US) 2024-11-20 EP disclosed
EP-4404932-A1 PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS Oric Pharmaceuticals, Inc. (US) 2024-07-31 EP disclosed
EP-4326723-A1 PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2024-02-28 EP disclosed
EP-4326719-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE Université de Montréal (CA) 2024-02-28 EP disclosed
CN-116828985-A Storage-stable aqueous suspension concentrates 拜耳公司 2023-09-29 CN disclosed
WO-2023133336-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. (US) 2023-07-13 WO disclosed
WO-2023049724-A1 PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS ORIC PHARMACEUTICALS, INC. (US) 2023-03-30 WO disclosed
WO-2023049723-A1 PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS ORIC PHARMACEUTICALS, INC. (US) 2023-03-30 WO disclosed
WO-2022221939-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE UNIVERSITE DE MONTREAL (CA) 2022-10-27 WO disclosed
WO-2022221940-A1 PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF UNIVERSITE DE MONTREAL (CA) 2022-10-27 WO disclosed